Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
- Xtandi Extends Overall Survival in Non-Metastatic CRPC
February 13, 2020
- Followup Data Backs Padcev-Keytruda Combo for 1st Line Bladder Cancer: Astellas/Seattle Genetics
February 13, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
- Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
February 10, 2020
- Chugai Joins NCC Scheme to Offer Free Drugs after Genomic Profiling
February 10, 2020
- After Erleada, Janssen Joins Hands with Nippon Shinyaku for Zytiga Too
February 10, 2020
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- I’rom Teams Up with Shanghai Public Health Clinical Center to Tackle Novel Coronavirus
February 10, 2020
- Novo Nordisk’s Fiasp Ultra-Fast Acting Insulin Now Available in Japan
February 10, 2020
- Japan Ethical Drug Sales Up 3.7% in December 2019: Crecon
February 10, 2020
- With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
- Keytruda’s Global Sales Cross US$10 Billion Mark in 2019, Tops Opdivo’s Including Asia
February 7, 2020
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Keytruda Stays Atop Encise’s January Drug Ranking
February 7, 2020
- Zeria Licenses Acofide to Spanish Pharma in 13 Latin American Countries
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…